Oncolytics Biotech Inc. (TSE:ONC – Get Rating) – Equities researchers at HC Wainwright lowered their Q1 2023 earnings estimates for shares of Oncolytics Biotech in a report issued on Tuesday, March 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.08) EPS, FY2023 earnings at ($0.35) EPS, FY2024 earnings at ($0.31) EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at ($0.06) EPS.
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a C$9.00 price target on shares of Oncolytics Biotech in a research note on Monday, March 6th.
Oncolytics Biotech Stock Up 8.8 %
About Oncolytics Biotech
Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.